FDA Risk Panel DXM Meeting Raises Stakes on Age Restriction Movement

A Drug Safety and Risk Management Advisory Committee meeting scheduled for Sept. 14 on the potential for abuse of the cough suppressant dextromethorphan could bring the OTC industry's next regulatory nightmare